32 results on '"Longo O"'
Search Results
2. Relationships between peroxidases and in vitro bulbification in garlic (Allium sativum L.)
- Author
-
Goleniowski, M., Del Longo, O., de Forchetti, S. M., and Argüello, J. A.
- Published
- 2001
- Full Text
- View/download PDF
3. Bonifica dei Terreni Contaminati. Osservazioni critiche, linee guida e proposte normative
- Author
-
Aggazzotti, Gabriella, Andretta, Alfonso, Benezzoli, Umberto, Bonifazi, Giuseppe, Butti, Luciano, Cappucci, Sergio, Davini, Andrea, Nauta, Stefano Di, Ferrante, Margherita, Finotelli, Fabrizio, Longo, Oronzo Antonio, Miano, Teodoro, Moretto, Carlo Giovanni, Orrico, Bruno, Pedron, Roberto, Peres, Federico, Pivato, Alberto, Quercia, Francesca, Racciatti, Rocco Virginio, Braschi, Ilaria, Bonifica dei terreni contaminati, in: Aggazzotti, G., Ajmone Marsan, F., Andretta, A., Andrisani, A. G., Angeloni, A., Arcella, C., Ardissone, E., Arena, U., Argese, E., Balestreri, A., Bavestrelli, A., Benezzoli, U., Bergamini, M., Bonifazi, G., Braschi, I., Bratti, A., Brutti, R., Butti, L., Canè, G., Cappucci, S., Castellano, G., Cervelli, M., Cianciullo, A., Cossu, R., Davini, A., Davit, J. P., Davoli, E., Dei Svaldi, M., Del Frate, A. A., Di Nauta, S., Di Sante, M., Dotti, M., Evangelista, R., Faleschini, F., Farina, R., Ferrante, M., Finotelli, F., Fogal, E., Forni, A., Forni, F., Furnari, S., Gnocchi, A., Gosso, E., Grisolia, M., Guerini, A., Lagorio, M., Lattanzi, P., Lavagnolo, M. C., Leombruni, A., Longo, O. A., Malagoli, M., Marotta, A., Massara, R., Massarini, P., Mastrantonio, M., Mazzieri, F., Miano, T., Misano, V., Monfroni, I., Morello, L., Moretto, C. G., Orrico, B., Parma, M., Pasqualini, E., Pedron, R., Peres, F., Petruzzelli, D., Petruzzelli, G. A., Piccolo, A., Pingitore, D., Pintore, M., Piscitelli, M., Pivato, A., Potenza, F., Potenza, G., Preda, G., Quercia, F., Racciati, R. V., Ranieri, G., Ranieri, M., Recchia, L., Ricci, R., Righini, L., Russo, P., Scalco, R., Schiavone, C., Spagni, A., Tasselli, L., Tonello, P., Tresso, G., Trevisi, V. M., Ursino, N., Vecchio, A., and Vinci, L.
- Published
- 2015
4. Waterfront San Leone. Il rapporto città-mare come infrastruttura inclusiva multiscala
- Author
-
Longo, O. and Orsini, Filippo
- Subjects
rigenerazione urbana ,Waterfront ,città ,progetto architettonico ,paesaggio ,infrastruttura ,infrastruttura, waterfront, rigenerazione urbana - Published
- 2012
5. Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART
- Author
-
Ensoli, B., Bellino, S., Tripiciano, A., Longo, O., Francavilla, V., Marcotullio, S., Cafaro, A., Picconi, O., Paniccia, G., Scoglio, A., Arancio, A., Ariola, C., Ruiz Alvarez, M. J., Campagna, M., Scaramuzzi, D., Iori, C., Esposito, R., Mussini, C., Ghinelli, F., Sighinolfi, L., Palamara, G., Latini, A., Angarano, G., Ladisa, N., Soscia, F., Mercurio, V. S., Lazzarin, A., Tambussi, G., Visintini, R., Mazzotta, F., Di Pietro, M., Galli, M., Rusconi, S., Carosi, G., Torti, C., Di Perri, G., Bonora, S., Ensoli, F., Garaci, E., and Segala, D.
- Subjects
CD4-Positive T-Lymphocytes ,Male ,T-Lymphocytes ,HIV Infections ,CD38 ,CD8-Positive T-Lymphocytes ,Lymphocyte Activation ,T-Lymphocytes, Regulatory ,Antiretroviral Therapy, Highly Active ,vaccine ,Cytotoxic T cell ,Homeostasis ,Killer Cells ,Prospective Studies ,tat ,Virology/Vaccines ,AIDS Vaccines ,B-Lymphocytes ,Multidisciplinary ,HIV ,AIDS ,Nausea ,Infectious Diseases/HIV Infection and AIDS ,Middle Aged ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,Combined Modality Therapy ,Regulatory ,Killer Cells, Natural ,medicine.anatomical_structure ,Treatment Outcome ,Virology/Immunodeficiency Viruses ,Natural ,Medicine ,tat Gene Products, Human Immunodeficiency Virus ,Female ,Adult ,Aged ,Asthenia ,HIV-1 ,Humans ,Immunization ,Cell activation ,tat Gene Products ,Human Immunodeficiency Virus ,Research Article ,Science ,T cell ,Antiretroviral Therapy ,Pathology/Immunology ,Biology ,NO ,Immune system ,Antigen ,Immunology/Immunity to Infections ,medicine ,Highly Active ,Virology ,Immunology ,CD8 - Abstract
UnlabelledAlthough HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated individuals. This is attributed to persistent virus expression in reservoirs and to cell activation. Of note, in CD4(+) T cells and monocyte-macrophages of virologically-suppressed individuals, there is continued expression of multi-spliced transcripts encoding HIV regulatory proteins. Among them, Tat is essential for virus gene expression and replication, either in primary infection or for virus reactivation during HAART, when Tat is expressed, released extracellularly and exerts, on both the virus and the immune system, effects that contribute to disease maintenance. Here we report results of an ad hoc exploratory interim analysis (up to 48 weeks) on 87 virologically-suppressed HAART-treated individuals enrolled in a phase II randomized open-label multicentric clinical trial of therapeutic immunization with Tat (ISS T-002). Eighty-eight virologically-suppressed HAART-treated individuals, enrolled in a parallel prospective observational study at the same sites (ISS OBS T-002), served for intergroup comparison. Immunization with Tat was safe, induced durable immune responses, and modified the pattern of CD4(+) and CD8(+) cellular activation (CD38 and HLA-DR) together with reduction of biochemical activation markers and persistent increases of regulatory T cells. This was accompanied by a progressive increment of CD4(+) T cells and B cells with reduction of CD8(+) T cells and NK cells, which were independent from the type of antiretroviral regimen. Increase in central and effector memory and reduction in terminally-differentiated effector memory CD4(+) and CD8(+) T cells were accompanied by increases of CD4(+) and CD8(+) T cell responses against Env and recall antigens. Of note, more immune-compromised individuals experienced greater therapeutic effects. In contrast, these changes were opposite, absent or partial in the OBS population. These findings support the use of Tat immunization to intensify HAART efficacy and to restore immune homeostasis.Trial registrationClinicalTrials.gov NCT00751595.
- Published
- 2010
6. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study
- Author
-
Bellino, S, Tripiciano, A, Picconi, O, Francavilla, V, Longo, O, Sgadari, C, Paniccia, G, Arancio, A, Angarano, G, Ladisa, N, Lazzarin, A, Tambussi, G, Nozza, S, Torti, C, Focà, E, Palamara, G, Latini, A, Sighinolfi, L, Mazzotta, F, Di Pietro, M, Di Perri, G, Bonora, S, Mercurio, V, Mussini, C, Gori, A, Galli, M, Monini, P, Cafaro, A, Ensoli, F, Ensoli, B, Ensoli, B., GORI, ANDREA, Bellino, S, Tripiciano, A, Picconi, O, Francavilla, V, Longo, O, Sgadari, C, Paniccia, G, Arancio, A, Angarano, G, Ladisa, N, Lazzarin, A, Tambussi, G, Nozza, S, Torti, C, Focà, E, Palamara, G, Latini, A, Sighinolfi, L, Mazzotta, F, Di Pietro, M, Di Perri, G, Bonora, S, Mercurio, V, Mussini, C, Gori, A, Galli, M, Monini, P, Cafaro, A, Ensoli, F, Ensoli, B, Ensoli, B., and GORI, ANDREA
- Abstract
Background: Tat is a key HIV-1 virulence factor, which plays pivotal roles in virus gene expression, replication, transmission and disease progression. After release, extracellular Tat accumulates in tissues and exerts effects on both the virus and the immune system, promoting immune activation and virus spreading while disabling the host immune defense. In particular, Tat binds Env spikes on virus particles forming a virus entry complex, which favors infection of dendritic cells and efficient transmission to T cells via RGD-binding integrins. Tat also shields the CCR5-binding sites of Env rendering ineffective virus neutralization by anti-Env antibodies (Abs). This is reversed by the anti-Tat Abs present in natural infection or induced by vaccination.Findings: Here we present the results of a cohort study, showing that the presence of anti-Tat Abs in asymptomatic and treatment-naïve HIV-infected subjects is associated with containment of CD4+ T-cell loss and viral load and with a delay of disease progression. In fact, no subjects with high anti-Tat Ab titers initiated antiretroviral therapy during the three years of follow-up. In contrast, no significant effects were seen for anti-Env and anti-Gag Abs. The increase of anti-Env Ab titers was associated with a reduced risk of starting therapy only in the presence of anti-Tat Abs, suggesting an effect of combined anti-Tat and anti-Env Abs on the Tat/Env virus entry complex and on virus neutralization.Conclusions: Anti-Tat immunity may help delay HIV disease progression, thus, targeting Tat may offer a novel therapeutic intervention to postpone antiretroviral treatment or to increase its efficacy. © 2014 Bellino et al.; licensee BioMed Central Ltd
- Published
- 2014
7. HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies
- Author
-
Sommer, P., Monini, P., Cafaro, A., Srivastava, I. K., Moretti, S., Sharma, V. A., Andreini, Claudia, Chiozzini, C., Ferrantelli, F., Pavone Cossut, M. R., Tripiciano, A., Nappi, F., Longo, O., Bellino, S., Picconi, O., Fanales Belasio, E., Borsetti, A., Toschi, E., Schiavoni, I., Bacigalupo, I., Kan, E., Sernicola, L., Maggiorella, M. T., Montin, K., Porcu, M., Leone, P., Collacchi, B., Palladino, C., Ridolfi, B., Falchi, M., Macchia, I., Ulmer, J. B., Buttò, S., Sgadari, C., Magnani, M., Federico, M. P. M., Titti, F., Banci, Lucia, Dallocchio, F., Rappuoli, R., Ensoli, F., Barnett, S. W., Garaci, E., and Ensoli, B.
- Subjects
Male ,Integrins ,T-Lymphocytes ,viruses ,lcsh:Medicine ,HIV Infections ,HIV Antibodies ,HIV Envelope Protein gp120 ,V3 loop ,Virus Replication ,Biochemistry ,Neutralization ,Epitope ,Molecular Cell Biology ,HIV vaccine ,lcsh:Science ,IMMUNODEFICIENCY-VIRUS TYPE-1 ,FIBROBLAST-GROWTH-FACTOR ,PROTEIN-PROTEIN DOCKING ,CYNOMOLGUS MONKEYS ,ENVELOPE PROTEIN ,KAPOSIS-SARCOMA ,STRUCTURAL CHARACTERIZATION ,THERAPEUTIC VACCINES ,PARTIAL DELETION ,GP120 CORE ,AIDS Vaccines ,Multidisciplinary ,Vaccination ,env Gene Products, Human Immunodeficiency Virus ,virus diseases ,Recombinant Proteins ,Extracellular Matrix ,Molecular Docking Simulation ,AIDS ,Cytochemistry ,Medicine ,Infectious diseases ,tat Gene Products, Human Immunodeficiency Virus ,Antibody ,Oligopeptides ,Protein Binding ,Research Article ,Receptors, CXCR4 ,Viral Entry ,Receptors, CCR5 ,Clinical Research Design ,Preclinical Models ,HIV prevention ,Sexually Transmitted Diseases ,Retrovirology and HIV immunopathogenesis ,Viral diseases ,Biology ,Microbiology ,Viral Attachment ,Virus ,Immune Deficiency ,Neutralization Tests ,Viral entry ,Virology ,Vaccine Development ,Cell Adhesion ,Animals ,Humans ,Protein Interaction Domains and Motifs ,Vaccines, Virus-Like Particle ,Immunity to Infections ,Binding Sites ,lcsh:R ,Immunity ,HIV ,Viral Vaccines ,TAT ,Dendritic Cells ,Virus Internalization ,Antibodies, Neutralizing ,Macaca fascicularis ,Viral replication ,HIV-1 ,biology.protein ,lcsh:Q ,Clinical Immunology ,Viral Transmission and Infection - Abstract
Use of Env in HIV vaccine development has been disappointing. Here we show that, in the presence of a biologically active Tat subunit vaccine, a trimeric Env protein prevents in monkeys virus spread from the portal of entry to regional lymph nodes. This appears to be due to specific interactions between Tat and Env spikes that form a novel virus entry complex favoring R5 or X4 virus entry and productive infection of dendritic cells (DCs) via an integrin-mediated pathway. These Tat effects do not require Tat-transactivation activity and are blocked by anti-integrin antibodies (Abs). Productive DC infection promoted by Tat is associated with a highly efficient virus transmission to T cells. In the Tat/Env complex the cysteine-rich region of Tat engages the Env V3 loop, whereas the Tat RGD sequence remains free and directs the virus to integrins present on DCs. V2 loop deletion, which unshields the CCR5 binding region of Env, increases Tat/Env complex stability. Of note, binding of Tat to Env abolishes neutralization of Env entry or infection of DCs by anti-HIV sera lacking anti-Tat Abs, which are seldom present in natural infection. This is reversed, and neutralization further enhanced, by HIV sera containing anti-Tat Abs such as those from asymptomatic or Tat-vaccinated patients, or by sera from the Tat/Env vaccinated monkeys. Thus, both anti-Tat and anti-Env Abs are required for efficient HIV neutralization. These data suggest that the Tat/Env interaction increases HIV acquisition and spreading, as a mechanism evolved by the virus to escape anti-Env neutralizing Abs. This may explain the low effectiveness of Env-based vaccines, which are also unlikely to elicit Abs against new Env epitopes exposed by the Tat/Env interaction. As Tat also binds Envs from different clades, new vaccine strategies should exploit the Tat/Env interaction for both preventative and therapeutic interventions.
- Published
- 2012
- Full Text
- View/download PDF
8. C-Raf antagonizes apoptosis induced by IFN-α in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A
- Author
-
Lamberti, A, primary, Longo, O, additional, Marra, M, additional, Tagliaferri, P, additional, Bismuto, E, additional, Fiengo, A, additional, Viscomi, C, additional, Budillon, A, additional, Rapp, U R, additional, Wang, E, additional, Venuta, S, additional, Abbruzzese, A, additional, Arcari, P, additional, and Caraglia, M, additional
- Published
- 2007
- Full Text
- View/download PDF
9. L’inquinamento atmosferico della città di Napoli: impostazione del problema, programmazione dei controlli, primi risultati attinenti alle polveri sedimentate raccolte durante l’anno 1973
- Author
-
Ortolani, G, Longo, O, Boccia, Antonio, DEL PRETE, U, and Gregorio, P.
- Published
- 1975
10. C-Raf antagonizes apoptosis induced by INF-a in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A
- Author
-
Eugenia Wang, Salvatore Venuta, M. Marra, Ulf R. Rapp, Alberto Abbruzzese, A Fiengo, Pierosandro Tagliaferri, Alfredo Budillon, Olimpia Longo, Caterina Viscomi, Ettore Bismuto, Michele Caraglia, Annalisa Lamberti, Paolo Arcari, Lamberti, Annalisa, Longo, O, Marra, M, Tagliaferri, P, Bismuto, E, Fiengo, A, Viscomi, C, Budillon, A, Rapp, U. P. WANG E, Venuta, S, Abbruzzese, A, Arcari, Paolo, Caraglia, M., Lamberti, A., Longo, O., Marra, M., Taglaferri, P., Bismuto, E., Fiengo, A., Viscomi, C., Budillon, A., Rapp, U., Wang, E., Venuta, S., ABBRUZZESE SACCARDI, A., Arcari, P., and Caraglia, Michele
- Subjects
Proteasome Endopeptidase Complex ,Programmed cell death ,Lung Neoplasms ,Alpha interferon ,Apoptosis ,Biology ,Phosphoserine ,Peptide Elongation Factor 1 ,Epidermal growth factor ,Cell Line, Tumor ,Humans ,Immunoprecipitation ,c-Raf ,Phosphorylation ,RNA, Small Interfering ,Kinase activity ,Molecular Biology ,Oncogene Proteins ,apoptosis ,Ubiquitin ,Interferon-alpha ,EF-1A ,Cell Biology ,Transfection ,Molecular biology ,Cell biology ,Proto-Oncogene Proteins c-raf ,C-Raf ,Protein Transport ,C-Raf, EF-1A, IFNα, apoptosis, proteasome, epidermoid cancer cells ,Phosphothreonine ,IFN-alpha ,Protein Processing, Post-Translational ,proteasome ,Protein Binding - Abstract
Interferon alpha (IFNalpha) induces both apoptosis and a counteracting epidermal growth factor Erk-dependent survival response in cancer cells. In this report, IFNalpha increased eukaryotic elongation factor 1A (eEF-1A) protein expression by inhibition of eEF-1A degradation via a proteasome-dependent pathway. The reduction of the expression level of eEF-1A by RNA interference enhanced the apoptosis induced by IFNalpha on the same cells. Moreover, IFNalpha induced the phosphorylation of both serine and threonine in eEF-1A. These effects were paralleled by an increased co-immunoprecipitation and colocalization of eEF-1A with C-Raf. The suppression of C-Raf kinase activity with the inhibitor BAY 43-9006 completely antagonized the increase of both eEF-1A phosphorylation and expression and of C-Raf/eEF-1A colocalization induced by IFNalpha and enhanced apoptosis and eEF-1A ubiquitination. Cell transfection with the mutated K48R ubiquitin increased EF-1A expression and desensitized tumor cells to the modulating effects of IFNalpha. The dynamic simulation of 3Dstructure of eEF-1A identified putative serine and threonine phosphorylation sites. In conclusion, the interaction between eEF-1A and C-Raf increases eEF-1A stability and induces a survival activity.
- Published
- 2007
11. Linearità e waterfront
- Author
-
Sbacchi, M., Longo, O, and Sbacchi, Michele
- Subjects
Settore ICAR/14 - Composizione Architettonica E Urbana ,linea, linearità - Abstract
Il waterfront è un luogo particolare sia per la città che per il progetto di architettura. Esistono due modi per intenderlo: uno perpendicolare ad esso ed uno orizzontale. Il primo è quello più tradizionale e scontato, il secondo invece meno diffuso ma di forte interesse.
- Published
- 2018
12. Paesaggio, architettura e trasformazioni urbane: scelte consapevoli per il terzo millennio
- Author
-
Leone, M., LONGO, O, AA.VV., and LEONE, Manfredi
- Subjects
Settore ICAR/15 - Architettura Del Paesaggio ,Paesaggio, Architettura, Natura, Citta', Trasformazione - Abstract
Il tema del rapporto tra architettura e natura e’ stato occasione secolare di esplorazione e ricerca. Nelle sue declinazioni piu recenti questo rapporto ha osservato una sempre maggiore integrazione tra concetti che possono apparire antinomici. Il bisogno di Natura in Architettura ottiene una consacrazione con il pensiero di Le Corbusier: il tetto-giardino prima, esplicitazione della integrazione della natura in architettura, che mette sull’edificio moderno la dimensione naturale normalmente destinata al livello del giardino. Successivamente gli studi sulla citta’ moderna e la sua integrazione con i sistemi naturali e il verde fanno di Le Corbusier un paesaggista innovatore; con la Ville Contemporaine per tre milioni di abitanti (1922), Il Plano Voisin per Parigi (1925), e la Ville Radieuse per un milione e mezzo di abitanti (1929), Le Corbusier trasforma in chiave contemporanea e dirompente le teorizzazioni di Howard sulla Città-Giardino, delineando in forma ipermoderna il nuovo rapporto tra natura e sistemi urbani, la cui qualità genera una totale integrazione tra artificio e natura, disciplinando altresí una nuova gerarchia negli spazi pubblici.Il saggio esplora esperienze di trasformazioni del paesaggio urbano.
- Published
- 2018
13. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
- Author
-
Petta, Salvatore, Marzioni, Marco, Russo, Pierluigi, Aghemo, Alessio, Alberti, Alfredo, ASCIONE, ANTONIO, Antinori, Andrea, Bruno, Raffaele, Bruno, Savino, Chirianni, Antonio, Gaeta, Giovanni Battista, Giannini, Edoardo G, Merli, Manuela, Messina, Vincenzo, Montilla, Simona, Perno, Carlo Federico, Puoti, Massimo, Raimondo, Giovanni, Rendina, Maria, Silberstein, Francesca Ceccherini, Villa, Erica, Zignego, Anna Linda, Pani, Luca, Craxì, Antonio, Tabone, Marco, Andreoni, Massimo, Teti, Elisabetta, Angelico, Mario, Persico, Marcello, Masarone, Mario, Chiodera, Aledssandro, Solinas, Attilio, delle Monache, Marco, Cecere, Roberto, Maria Schimizzi, Anna, Piovesan, Sara, Campagnolo, Davide, Chiara Piras, Maria, Zolfino, Teresa, Paolo Russo, Francesca, Morelli, Olivia, Sangiovanni, Vincenzo, Onofrio, Mirella, Iodice, Valentina, Izzi, Antonio, Pirisi, Massimo, Danieli, Elena, Vinci, Maria, Rizzardini, Giuliano, Fagiuoli, Stefano, Pasulo, Luisa, D'Arminio Monforte, Antonella, Zuin, Massimo, Giorgini, Alessia, Simeone, Filomena, Piali, Guido, Lo Guercio, Carmela, Federico, Alessandro, Brancaccio, Giuseppina, Marrone, Aldo, Abbati, Giuseppe, Boarini, Chiara, Borghi, Vanni, Bernabucci, Veronica, Corti, Giampaolo, Monti, Monica, Rizzetto, Mario, Martini, Silvia, Andreone, Pietro, Gianstefani, Alice, Lenzi, Marco, Verucchi, Gabriella, Toniutto, Pierluigi, Borgia, Guglielmo, Caporaso, Nicola, Morisco, Filomena, Nardone, Gaetano, Angrisani, Debora, Giacometti, Andrea, Benedetti, Antonio, Tarantino, Giuseppe, Marsetti, Fabio, Tavio, Marcello, Novara, Sergio, Antonia Santantonio, Teresa, Serviddio, Gaetano, Brunetto, Maurizia, Coco, Barbara, Angarano, Gioacchino, Milella, Michele, BARONE, MICHELE, Di Leo, Alfredo, Ettore Sansonno, Domenico, Cacciola, Irene, Boffa, Nicola, Saracco, Giorgio, Di Biagio, Antonio, Picciotto, Antonino, de Luca, Andrea, Calvaruso, Vincenza, Corradori, Silvia, Ferrari, Carlo, Orlandini, Alessandra, Maida, Ivana, Torti, Carlo, Chessa, Luchino, Felder, Martina, Vespasiani Gentilucci, Umberto, Angeli, Paolo, Romano, Antonietta, Ludovico Rapaccini, Gian, Miele, Luca, Cima, Serena, Luisa Russo, Maria, Cozzolongo, Raffaele, Onnelli, Giovanna, D'Offizi, Giampiero, Lionetti, Raffaella, Montalbano, Marzia, Guerra, Michele, Di Perri, Giovanni, Boglione, Lucio, Capra, Franco, Carolo, Giada, Ieluzzi, Donatella, Antonini, Cinzia, Termite, Antonio, Madonia, Salvatore, Tarquini, Pierluigi, Parruti, Giustino, Vecchiet, Giacomo, Falasca, Katia, Menzaghi, Barbara, Quirino, Tiziana, Dentone, Chiara, Maria Piscaglia, Anna, Rossi, Cristina, Giordani, Maria, Fontanella, Luca, Cassola, Giovanni, Russello, Maurizio, Cristaudo, Antonio, Giacomet, Vania, Colombo, Massimo, Donato, Francesca, Durante, Emanuele, Cosco, Lucio, Marignani, Massimo, Quartini, Mariano, Memoli, Massimo, Ganga, Roberto, Ponti, Laura, Soria, Alessandro, Grazia Rumi, Maria, Gulminetti, Roberto, Maserati, Renato, Mondelli, Mario, Lazzarin, Adriano, Rita Parisi, Maria, Canovari, Benedetta, Avancini, Ivo, Pravadelli, Cecilia, Blanc, Pier, Pasquazzi, Caterina, Maria Mastroianni, Claudio, Lichtner, Myriam, Distefano, Marco, Magnani, Silvia, Paganin, Simona, Erne, Elke, Gatti, Pietro, Tundi, Paolo, Calabrese, Paolo, Gasbarrini, Antonio, Grieco, Antonio, Coppola, Nicola, Del Poggio, Paolo, Levrero, Massimo, Talliani, Gloria, Vullo, Vincenzo, Cauda, Roberto, La Monica, Silvia, Potenza, Domenico, Rizzo, Salvatore, Castelli, Francesco, Marie Pigozzi, Grazielle, Ciancio, Alessia, Romagnoli, Dante, Barchetti, Federica, Ivanovic, Jelena, Longo, Olimpia, Petraglia, Sandra, Paola Trotta, Maria, NARDONE, GERARDO ANTONIO PIO, Petta, Salvatore, Marzioni, Marco, Russo, Pierluigi, Aghemo, Alessio, Alberti, Alfredo, Ascione, Antonio, Antinori, Andrea, Bruno, Raffaele, Bruno, Savino, Chirianni, Antonio, Gaeta, Giovanni Battista, Giannini, Edoardo G, Merli, Manuela, Messina, Vincenzo, Montilla, Simona, Perno, Carlo Federico, Puoti, Massimo, Raimondo, Giovanni, Rendina, Maria, Silberstein, Francesca Ceccherini, Villa, Erica, Zignego, Anna Linda, Pani, Luca, Craxì, Antonio, Tabone, Marco, Andreoni, Massimo, Teti, Elisabetta, Angelico, Mario, Persico, Marcello, Masarone, Mario, Chiodera, Aledssandro, Solinas, Attilio, delle Monache, Marco, Cecere, Roberto, Maria Schimizzi, Anna, Piovesan, Sara, Campagnolo, Davide, Chiara Piras, Maria, Zolfino, Teresa, Paolo Russo, Francesca, Morelli, Olivia, Sangiovanni, Vincenzo, Onofrio, Mirella, Iodice, Valentina, Izzi, Antonio, Pirisi, Massimo, Danieli, Elena, Vinci, Maria, Rizzardini, Giuliano, Fagiuoli, Stefano, Pasulo, Luisa, D'Arminio Monforte, Antonella, Zuin, Massimo, Giorgini, Alessia, Simeone, Filomena, Piali, Guido, Lo Guercio, Carmela, Federico, Alessandro, Brancaccio, Giuseppina, Marrone, Aldo, Abbati, Giuseppe, Boarini, Chiara, Borghi, Vanni, Bernabucci, Veronica, Corti, Giampaolo, Monti, Monica, Rizzetto, Mario, Martini, Silvia, Andreone, Pietro, Gianstefani, Alice, Lenzi, Marco, Verucchi, Gabriella, Toniutto, Pierluigi, Borgia, Guglielmo, Caporaso, Nicola, Morisco, Filomena, Nardone, Gaetano, Angrisani, Debora, Giacometti, Andrea, Benedetti, Antonio, Tarantino, Giuseppe, Marsetti, Fabio, Tavio, Marcello, Novara, Sergio, Antonia Santantonio, Teresa, Serviddio, Gaetano, Brunetto, Maurizia, Coco, Barbara, Angarano, Gioacchino, Milella, Michele, Barone, Michele, Di Leo, Alfredo, Ettore Sansonno, Domenico, Cacciola, Irene, Boffa, Nicola, Saracco, Giorgio, Di Biagio, Antonio, Picciotto, Antonino, de Luca, Andrea, Calvaruso, Vincenza, Corradori, Silvia, Ferrari, Carlo, Orlandini, Alessandra, Maida, Ivana, Torti, Carlo, Chessa, Luchino, Felder, Martina, Vespasiani Gentilucci, Umberto, Angeli, Paolo, Romano, Antonietta, Ludovico Rapaccini, Gian, Miele, Luca, Cima, Serena, Luisa Russo, Maria, Cozzolongo, Raffaele, Onnelli, Giovanna, D'Offizi, Giampiero, Lionetti, Raffaella, Montalbano, Marzia, Guerra, Michele, Di Perri, Giovanni, Boglione, Lucio, Capra, Franco, Carolo, Giada, Ieluzzi, Donatella, Antonini, Cinzia, Termite, Antonio, Madonia, Salvatore, Tarquini, Pierluigi, Parruti, Giustino, Vecchiet, Giacomo, Falasca, Katia, Menzaghi, Barbara, Quirino, Tiziana, Dentone, Chiara, Maria Piscaglia, Anna, Rossi, Cristina, Giordani, Maria, Fontanella, Luca, Cassola, Giovanni, Russello, Maurizio, Cristaudo, Antonio, Giacomet, Vania, Colombo, Massimo, Donato, Francesca, Durante, Emanuele, Cosco, Lucio, Marignani, Massimo, Quartini, Mariano, Memoli, Massimo, Ganga, Roberto, Ponti, Laura, Soria, Alessandro, Grazia Rumi, Maria, Gulminetti, Roberto, Maserati, Renato, Mondelli, Mario, Lazzarin, Adriano, Rita Parisi, Maria, Canovari, Benedetta, Avancini, Ivo, Pravadelli, Cecilia, Blanc, Pier, Pasquazzi, Caterina, Maria Mastroianni, Claudio, Lichtner, Myriam, Distefano, Marco, Magnani, Silvia, Paganin, Simona, Erne, Elke, Gatti, Pietro, Tundi, Paolo, Calabrese, Paolo, Gasbarrini, Antonio, Grieco, Antonio, Coppola, Nicola, Del Poggio, Paolo, Levrero, Massimo, Talliani, Gloria, Vullo, Vincenzo, Cauda, Roberto, La Monica, Silvia, Potenza, Domenico, Rizzo, Salvatore, Castelli, Francesco, Marie Pigozzi, Grazielle, Ciancio, Alessia, Romagnoli, Dante, Barchetti, Federica, Ivanovic, Jelena, Longo, Olimpia, Petraglia, Sandra, Paola Trotta, Maria, Petta, S., Marzioni, M., Russo, P., Aghemo, A., Alberti, A., Ascione, A., Antinori, A., Bruno, R., Bruno, S., Chirianni, A., Gaeta, G., Giannini, E., Merli, M., Messina, V., Montilla, S., Perno, C., Puoti, M., Raimondo, G., Rendina, M., Silberstein, F., Villa, E., Zignego, A., Pani, L., Craxi, A., Tabone, M., Andreoni, M., Teti, E., Angelico, M., Persico, M., Masarone, M., Chiodera, A., Solinas, A., delle Monache, M., Cecere, R., Maria Schimizzi, A., Piovesan, S., Campagnolo, D., Chiara Piras, M., Zolfino, T., Paolo Russo, F., Morelli, O., Sangiovanni, V., Onofrio, M., Iodice, V., Izzi, A., Pirisi, M., Danieli, E., Vinci, M., Rizzardini, G., Fagiuoli, S., Pasulo, L., D'Arminio Monforte, A., Zuin, M., Giorgini, A., Simeone, F., Piali, G., Lo Guercio, C., Federico, A., Brancaccio, G., Marrone, A., Abbati, G., Boarini, C., Borghi, V., Bernabucci, V., Corti, G., Monti, M., Rizzetto, M., Martini, S., Andreone, P., Gianstefani, A., Lenzi, M., Verucchi, G., Toniutto, P., Borgia, G., Caporaso, N., Morisco, F., Nardone, G., Angrisani, D., Giacometti, A., Benedetti, A., Tarantino, G., Marsetti, F., Tavio, M., Novara, S., Antonia Santantonio, T., Serviddio, G., Brunetto, M., Coco, B., Angarano, G., Milella, M., Barone, M., Di Leo, A., Ettore Sansonno, D., Cacciola, I., Boffa, N., Saracco, G., Di Biagio, A., Picciotto, A., de Luca, A., Calvaruso, V., Corradori, S., Ferrari, C., Orlandini, A., Maida, I., Torti, C., Chessa, L., Felder, M., Vespasiani Gentilucci, U., Angeli, P., Romano, A., Ludovico Rapaccini, G., Miele, L., Cima, S., Luisa Russo, M., Cozzolongo, R., Onnelli, G., D'Offizi, G., Lionetti, R., Montalbano, M., Guerra, M., Di Perri, G., Boglione, L., Capra, F., Carolo, G., Ieluzzi, D., Antonini, C., Termite, A., Madonia, S., Tarquini, P., Parruti, G., Vecchiet, G., Falasca, K., Menzaghi, B., Quirino, T., Dentone, C., Maria Piscaglia, A., Rossi, C., Giordani, M., Fontanella, L., Cassola, G., Russello, M., Cristaudo, A., Giacomet, V., Colombo, M., Donato, F., Durante, E., Cosco, L., Marignani, M., Quartini, M., Memoli, M., Ganga, R., Ponti, L., Soria, A., Grazia Rumi, M., Gulminetti, R., Maserati, R., Mondelli, M., Lazzarin, A., Rita Parisi, M., Canovari, B., Avancini, I., Pravadelli, C., Blanc, P., Pasquazzi, C., Maria Mastroianni, C., Lichtner, M., Distefano, M., Magnani, S., Paganin, S., Erne, E., Gatti, P., Tundi, P., Calabrese, P., Gasbarrini, A., Grieco, A., Coppola, N., Del Poggio, P., Levrero, M., Talliani, G., Vullo, V., Cauda, R., La Monica, S., Potenza, D., Rizzo, S., Castelli, F., Marie Pigozzi, G., Ciancio, A., Romagnoli, D., Barchetti, F., Ivanovic, J., Longo, O., Petraglia, S., Paola Trotta, M., Savino, Bruno, Nardone, GERARDO ANTONIO PIO, Petta, S, Marzioni, M, Russo, P, Aghemo, A, Alberti, A, Ascione, A, Antinori, A, Bruno, R, Bruno, S, Chirianni, A, Gaeta, G, Giannini, E, Merli, M, Messina, V, Montilla, S, Perno, C, Puoti, M, Raimondo, G, Rendina, M, Silberstein, F, Villa, E, Zignego, A, Pani, L, Craxì, A, and Fagiuoli, S
- Subjects
Cyclopropanes ,Compassionate Use Trials ,Liver Cirrhosis ,Male ,chemistry.chemical_compound ,0302 clinical medicine ,2-Naphthylamine ,HCV, direct-acting antiviral, mixed cryoglobulinemia, RBV ,Anilides ,030212 general & internal medicine ,Longitudinal Studies ,Prospective Studies ,Chronic ,Adult ,Aged ,Antiviral Agents ,Carbamates ,Drug Therapy, Combination ,Female ,Genotype ,Hepatitis C, Chronic ,Humans ,Macrocyclic Compounds ,Middle Aged ,Ribavirin ,Ritonavir ,Sulfonamides ,Treatment Outcome ,Uracil ,Settore MED/12 - Gastroenterologia ,Dasabuvir ,HCV DAA ,Gastroenterology ,virus diseases ,Valine ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,Hepatitis C ,Hepatology ,Combination ,030211 gastroenterology & hepatology ,medicine.drug ,medicine.medical_specialty ,Proline ,Lactams, Macrocyclic ,Hepatitis C virus genotype 1, Hepatitis C virus genotype 4, decompensated liver cirrhosis, antiviral therapy, dasabuvir, ombitasvir, paritaprevir ,03 medical and health sciences ,Drug Therapy ,Internal medicine ,medicine ,Decompensation ,Adverse effect ,business.industry ,Virology ,Ombitasvir ,Clinical trial ,chemistry ,Paritaprevir ,business - Abstract
Summary Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. Methods In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once daily and dasabuvir (250 mg) twice daily for 12 weeks (patients with HCV genotype 1b infection) or 24 weeks (patients with HCV genotype 1a infection). Patients with HCV genotype 4 infection were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once per day for 24 weeks. All patients were given weight-based ribavirin. The primary efficacy endpoint was sustained virological response at week 12 after the end of treatment (SVR12), analysed by intention-to-treat. Univariate and multivariate logistic regression analyses were used to identify baseline characteristics associated with SVR12. Adverse events were recorded throughout the study. Findings 728 (96%) of 762 patients with cirrhosis who were given ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin therapy for 12 or 24 weeks achieved SVR12. Logistic regression analyses identified that bilirubin concentrations of less than 2 mg/dL were associated with SVR12 (odds ratio [OR] 4·76 [95% CI 1·83–12·3]; p=0·001). 166 (23%) of 734 patients included in safety analyses had an adverse event. 25 (3%) patients discontinued treatment because of adverse events. Asthenia was the most commonly reported adverse event, occurring in 36 (5%) patients. Interpretation Our findings suggest that the safety and effectiveness of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin in patients with HCV genotype 1 or 4 infection and cirrhosis at high risk of decompensation in a real-life setting are similar to those reported in clinical trials. The concordance with clinical trials provides reassurance that the reported efficacy of this treatment in clinical trials will translate to its use in routine clinical practice. Funding Dipartimento Biomedico di Medicina Interna e Specialistica dell'Universita di Palermo.
- Published
- 2017
14. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial
- Author
-
Laura Sighinolfi, Guido Palamara, Massimo Di Pietro, Barbara Ensoli, Angela Arancio, Sonia Moretti, Mauro Magnani, Stefania Bellino, Fabrizio Ensoli, Vito S. Mercurio, Francesco Castelli, Leonardo Sernicola, Enrico Garaci, Maria Teresa Maggiorella, Andrea Gori, Giovanni Di Perri, Cecilia Sgadari, Massimo Galli, Vittorio Francavilla, Orietta Picconi, Anna Casabianca, Olimpia Longo, Chiara Orlandi, Aurelio Cafaro, Adriano Lazzarin, Antonella Tripiciano, Cristina Mussini, Maria Rosaria Pavone Cossut, Giovanni Paniccia, Gioacchino Angarano, Paolo Monini, Ensoli, F, Cafaro, A, Casabianca, A, Tripiciano, A, Bellino, S, Longo, O, Francavilla, V, Picconi, O, Sgadari, C, Moretti, S, Cossut, M, Arancio, A, Orlandi, C, Sernicola, L, Maggiorella, M, Paniccia, G, Mussini, C, Lazzarin, A, Sighinolfi, L, Palamara, G, Gori, A, Angarano, G, Di Pietro, M, Galli, M, Mercurio, V, Castelli, F, Di Perri, G, Monini, P, Magnani, M, Garaci, E, and Ensoli, B
- Subjects
Male ,HAART ,Antibodie ,HIV Antibodies ,CD38 ,Antibodies ,CD38+HLA-DR+/CD8+ T cells ,HIV-1 ,Neutralization ,Proviral DNA ,Tat protein ,Vaccine ,AIDS Vaccines ,Acquired Immunodeficiency Syndrome ,Adult ,Antibodies, Neutralizing ,Antiretroviral Therapy, Highly Active ,CD4 Lymphocyte Count ,Female ,Follow-Up Studies ,Humans ,Immunoglobulin G ,Immunoglobulin M ,Italy ,Leukocytes ,Middle Aged ,Treatment Outcome ,Young Adult ,tat Gene Products, Human Immunodeficiency Virus ,Viral Load ,Virology ,Infectious Diseases ,Medicine ,+ ,HLA-DR ,CD8 ,T cells ,Neutralizing ,biology ,Immunogenicity ,Vaccination ,CD38+HLA-DR+/CD8+ T cell ,Antibody ,tat Gene Products ,Viral load ,Human Immunodeficiency Virus ,Antiretroviral Therapy ,Viremia ,Immune system ,Highly Active ,business.industry ,Research ,medicine.disease ,Immunization ,Immunology ,biology.protein ,business - Abstract
Background The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov NCT00751595) was aimed at evaluating the immunogenicity and the safety of the biologically active HIV-1 Tat protein administered at 7.5 or 30 μg, given 3 or 5 times monthly, and at exploring immunological and virological disease biomarkers. The study duration was 48 weeks, however, vaccinees were followed until the last enrolled subject reached the 48 weeks. Reported are final data up to 144 weeks of follow-up. The ISS T-002 trial was conducted in 11 clinical centers in Italy on 168 HIV positive subjects under Highly Active Antiretroviral Therapy (HAART), anti-Tat Antibody (Ab) negative at baseline, with plasma viremia
- Published
- 2015
- Full Text
- View/download PDF
15. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study
- Author
-
Giuseppe Tambussi, Paolo Monini, Giovanni Paniccia, Guido Palamara, Angela Arancio, Emanuele Focà, Alessandra Latini, Massimo Di Pietro, Vito S. Mercurio, Fabrizio Ensoli, Laura Sighinolfi, Giovanni Di Perri, Antonella Tripiciano, Stefania Bellino, Orietta Picconi, Cecilia Sgadari, Andrea Gori, Cristina Mussini, Olimpia Longo, Stefano Bonora, Gioacchino Angarano, Nicoletta Ladisa, Vittorio Francavilla, Massimo Galli, Silvia Nozza, Francesco Mazzotta, Barbara Ensoli, Aurelio Cafaro, Adriano Lazzarin, Carlo Torti, Bellino, S, Tripiciano, A, Picconi, O, Francavilla, V, Longo, O, Sgadari, C, Paniccia, G, Arancio, A, Angarano, G, Ladisa, N, Lazzarin, A, Tambussi, G, Nozza, S, Torti, C, Focà, E, Palamara, G, Latini, A, Sighinolfi, L, Mazzotta, F, Di Pietro, M, Di Perri, G, Bonora, S, Mercurio, V, Mussini, C, Gori, A, Galli, M, Monini, P, Cafaro, A, Ensoli, F, and Ensoli, B
- Subjects
CD4-Positive T-Lymphocytes ,Male ,Antibodie ,viruses ,HIV Infections ,Antibodies, Viral ,AIDS Vaccine ,Virulence factor ,Cohort Studies ,chemistry.chemical_compound ,HIV Infection ,Viral load ,Viral ,Neutralizing ,AIDS Vaccines ,tat Gene Products, Human Immunodeficiency Viru ,Medicine (all) ,Infectious Diseases ,CD4-Positive T-Lymphocyte ,Disease Progression ,tat Gene Products, Human Immunodeficiency Virus ,Female ,Antibody ,tat Gene Products ,Human Immunodeficiency Virus ,Human ,Adult ,CD4 antigen ,Antibodies ,HIV progression ,Tat ,Antibodies, Neutralizing ,Gene Products, env ,Genes, env ,HIV-1 ,Humans ,Viral Load ,Virology ,Short Report ,Infectious Disease ,Biology ,Virus ,Immune system ,Viral entry ,Gene Products ,env ,CD4+ T cells ,Genes ,chemistry ,Immunization ,Immunology ,biology.protein ,Cohort Studie - Abstract
Background: Tat is a key HIV-1 virulence factor, which plays pivotal roles in virus gene expression, replication, transmission and disease progression. After release, extracellular Tat accumulates in tissues and exerts effects on both the virus and the immune system, promoting immune activation and virus spreading while disabling the host immune defense. In particular, Tat binds Env spikes on virus particles forming a virus entry complex, which favors infection of dendritic cells and efficient transmission to T cells via RGD-binding integrins. Tat also shields the CCR5-binding sites of Env rendering ineffective virus neutralization by anti-Env antibodies (Abs). This is reversed by the anti-Tat Abs present in natural infection or induced by vaccination.Findings: Here we present the results of a cohort study, showing that the presence of anti-Tat Abs in asymptomatic and treatment-naïve HIV-infected subjects is associated with containment of CD4+ T-cell loss and viral load and with a delay of disease progression. In fact, no subjects with high anti-Tat Ab titers initiated antiretroviral therapy during the three years of follow-up. In contrast, no significant effects were seen for anti-Env and anti-Gag Abs. The increase of anti-Env Ab titers was associated with a reduced risk of starting therapy only in the presence of anti-Tat Abs, suggesting an effect of combined anti-Tat and anti-Env Abs on the Tat/Env virus entry complex and on virus neutralization.Conclusions: Anti-Tat immunity may help delay HIV disease progression, thus, targeting Tat may offer a novel therapeutic intervention to postpone antiretroviral treatment or to increase its efficacy. © 2014 Bellino et al.; licensee BioMed Central Ltd
- Published
- 2014
- Full Text
- View/download PDF
16. Surface-bound Tat inhibits antigen-specific CD8(+) T-cell activation in an integrin-dependent manner
- Author
-
Filomena Nappi, Fabrizio Ensoli, Chiara Chiozzini, Antonella Tripiciano, Olimpia Longo, Aurelio Cafaro, Claudia Arenaccio, Barbara Collacchi, Maurizio Federico, Tanja Bauer, Barbara Ensoli, Chiozzini, C, Collacchi, B, Nappi, F, Bauer T.,, Arenaccio, Claudia, Tripiciano, A, Longo, O, Ensoli, F, Cafaro, A, Ensoli, B, and Federico, M.
- Subjects
Adult ,Male ,Integrins ,Immunology ,Integrin ,Apoptosis ,CD8-Positive T-Lymphocytes ,CD8(+) T cell ,Cell membrane ,Young Adult ,Antigen ,medicine ,Extracellular ,Humans ,Immunology and Allergy ,Cytotoxic T cell ,Interferon gamma ,biology ,Molecular biology ,apoptosi ,Infectious Diseases ,medicine.anatomical_structure ,Host-Pathogen Interactions ,HIV-1 ,biology.protein ,Female ,tat Gene Products, Human Immunodeficiency Virus ,Tat ,Cell activation ,CD8 ,medicine.drug - Abstract
Objective:The identification of still unrevealed mechanisms affecting the anti-HIV CD8(+) T-cell response in HIV-1 infection.Design:Starting from the observation that anti-Tat immunization is associated with improved CD8(+) T-cell immunity, we developed both in-vitro and ex-vivo assays to characterize the effects of extra-cellular Tat on the adaptive CD8(+) T-cell response.Methods:The effects of Tat on CD8(+) T-cell activation were assayed using CD8(+) T-cell clones specific for either cellular (MART-1) or viral (HIV-1 Nef) antigens, and HIV-1 Gag-specific CD8(+) T cells from HIV-1 patients.Results:The interaction between CD8(+) T lymphocytes and immobilized Tat, but not its soluble form, inhibits peptide-specific CD8(+) T-lymphocyte activation. The inhibition does not depend on Tat trans-activation activity, but on the interaction of the Tat RGD domain with 51 and v3 integrins. Impaired CD8(+) T-cell activation was also observed in cocultures of CD8(+) T cells with HIV-1-infected cells. Anti-Tat Abs abrogate the inhibitory effect, consistently with the evidence that extracellular Tat accumulates on the cell membrane of virus-producing cells. The Tat-induced inhibition of cell activation associates with increased apoptosis of CD8(+) T cells. Finally, the inhibition of cell activation also takes place in Gag-specific CD8(+) T lymphocytes from HIV-1-infected patients.Conclusion:Our results support the idea that CD8(+) T-cell apoptosis induced by surface-bound extracellular Tat can contribute to the dysregulation of the CD8(+) T-cell adaptive response against HIV as well as other pathogens present in AIDS patients.
- Published
- 2014
17. A Long Acidic Domain Affects the Chromatographic Behaviour of a Neuronal Adaptor Protein on DEAE-Sepharose
- Author
-
Annalisa Lamberti, Olimpia Longo, Nicola Zambrano, Paolo Arcari, Longo, O., Lamberti, Annalisa, Zambrano, N., and Arcari, Paolo
- Subjects
inorganic chemicals ,Blotting, Western ,Magnesium Chloride ,chemistry.chemical_element ,Nerve Tissue Proteins ,Calcium ,Applied Microbiology and Biotechnology ,Biochemistry ,Analytical Chemistry ,Calcium Chloride ,chemistry.chemical_compound ,Protein structure ,Western blot ,medicine ,Animals ,Molecular Biology ,Chromatography ,medicine.diagnostic_test ,Sepharose ,Osmolar Concentration ,Organic Chemistry ,Nuclear Proteins ,Signal transducing adaptor protein ,General Medicine ,Glutamic acid ,Peptide Fragments ,Protein Structure, Tertiary ,Rats ,Blot ,chemistry ,DEAE-Sepharose ,Ionic strength ,Chromatography, Liquid ,Biotechnology - Abstract
The stepwise chromatographic behaviour on DEAE-Sepharose of rat Fe65, a neuronal protein, was tested, using as eluants KCl, CaCl2, and MgCl2. Assays by western blot showed that Fe65 was eluted by CaCl2, at a ionic strength 20% lower than that of MgCl2 or KCl. Interestingly, in the case of a truncated Fe65, lacking a glutamic acid rich region at the N-terminus, the ionic strengths of the various eluants were almost identical. These results suggested a possible inhibitory role of calcium ions in the binding of the protein to DEAE and a specific affinity of these ions for long acidic stretches.
- Published
- 2003
- Full Text
- View/download PDF
18. Palestra Puglisi. Bagheria
- Author
-
LEONE, Giuseppe, LONGO, Olivia, ODDO M., LEONE G, and Longo, O.
- Subjects
architettura contemporanea ,attrezzature sportive - Published
- 2007
19. The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: Review article
- Author
-
Alberto Abbruzzese, M. Marra, Annalisa Lamberti, Paolo Arcari, Michele Caraglia, Olimpia Longo, Lamberti, A, Caraglia, Michele, Longo, O, Marra, M, Abbruzzese, A, Arcari, P., Lamberti, Annalisa, M., Caraglia, Longo, Olimpia, M., Marra, A., Abbruzzese, and Arcari, Paolo
- Subjects
Ubiquitin ,Organic Chemistry ,Clinical Biochemistry ,Apoptosis ,Autophagy-related protein 13 ,Biology ,Protein degradation ,Biochemistry ,Eukaryotic translation elongation factor 1 alpha 1 ,Cell biology ,Elongation factor ,Translation elongation factor 1A – Protein synthesis – Ubiquitin – Interferon ,EIF4EBP1 ,Cell Transformation, Neoplastic ,Peptide Elongation Factor 1 ,Protein biosynthesis ,Animals ,Phosphorylation ,Signal transduction ,Protein Processing, Post-Translational ,Signal Transduction - Abstract
An increasing number of evidences suggest the involvement of the eukaryotic elongation factor 1A, a core component of the protein synthesis machinery, at the onset of cell transformation. In fact, eEF1A is shown to be up-regulated in cell death; moreover, it seems to be involved in the regulation of ubiquitin-mediated protein degradation. In addition, eEF1A undergoes several post-translational modifications, mainly phosphorylation and methylation, that generally influence the activity of the protein. This article summarizes the present knowledges on the several extra-translational roles of eEF1A also in order to understand as the protein synthesis regulatory mechanisms could offer tools for cancer intervention.
- Published
- 2004
- Full Text
- View/download PDF
20. FROM VISION TO ACTION: A NEUROMIMETIC MODEL OF THE SACCADIC SYSTEM
- Author
-
QUAIA, CHRISTIAN, INCHINGOLO, PAOLO, and LONGO, O. GIUSEPPE
- Subjects
INGEGNERIA DELL'INFORMAZIONE - Abstract
1999/2000 XIII Ciclo 1970 Versione digitalizzata della tesi di dottorato cartacea.
- Published
- 2001
21. NONLINEAR OPERATORS FOR IMAGE PROCESSING: DESIGN, IMPLEMENTATION AND MODELING TECHNIQUES FOR POWER ESTIMATION
- Author
-
BERNACCHIA, GIUSEPPE, SICURANZA, GIOVANNI, and LONGO, O. GIUSEPPE
- Subjects
INGEGNERIA DELL'INFORMAZIONE - Abstract
1998/1999 Negli ultimi anni passati le applicazioni multimediali hanno visto uno sviluppo notevole, trovando applicazione in un gran numero di campi. Applicazioni come video conferenze, diagnostica medica, telefonia mobile e applicazioni militari necessitano il trattamento di una gran mole di dati ad alta velocità. Pertanto, l'elaborazione di immagini e di dati vocali è molto importante ed è stata oggetto di numerosi sforzi, nel tentativo di trovare algoritmi sempre più veloci ed efficaci. Tra gli algoritmi proposti, noi crediamo che gli operatori razionali svolgano un ruolo molto importante, grazie alla loro versatilità ed efficacia nell'elaborazione di dati. Negli ultimi anni sono stati proposti diversi algoritmi, dimostrando che questi operatori possono essere molto vantaggiosi in diverse applicazioni, producendo buoni risultati. Lo scopo di questo lavoro è di realizzare alcuni di questi algoritmi e, quindi, dimostrare che i filtri razionali, in particolare, possono essere realizzati senza ricorrere a sistemi di grandi dimensioni e possono raggiungere frequenze operative molto alte. Una volta che il blocco fondamentale di un sistema basato su operatori razionali sia stato realizzato, esso pu6 essere riusato con successo in molte altre applicazioni. Dal punto di vista del progettista, è importante avere uno schema generale di studio, che lo renda capace di studiare le varie configurazioni del sistema da realizzare e di analizzare i compromessi tra le variabili di progetto. In particolare, per soddisfare l'esigenza di metodi versatili per la stima della potenza, abbiamo sviluppato una tecnica di macro modellizazione che permette al progettista di stimare velocemente ed accuratamente la potenza dissipata da un circuito. La tesi è organizzata come segue: Nel Capitolo 1 alcuni sono presentati alcuni algoritmi studiati per la realizzazione. Ne viene data solo una veloce descrizione, lasciando comunque al lettore interessato dei riferimenti bibliografici. Nel Capitolo 2 vengono discusse le architetture fondamentali usate per la realizzazione. Principalmente sono state usate architetture a pipeline, ma viene data anche una descrizione degli approcci oggigiorno disponibili per l'ottimizzazione delle temporizzazioni. Nel Capitolo 3 sono presentate le realizzazioni di due sistemi studiati per questa tesi. Gli approcci seguiti si basano su ASIC e FPGA. Richiedono tecniche e soluzioni diverse per il progetto del sistema, per cui é interessante vedere cosa pu6 essere fatto nei due casi. Infine, nel Capitolo 4, descriviamo la nostra tecnica di macro modellizazione per la stima di potenza, dando una breve visione delle tecniche finora proposte e facendo vedere quali sono i vantaggi che il nostro metodo comporta per il progetto. In the past few years, multimedia application have been growing very fast, being applied to a large variety of fields. Applications like video conference, medical diagnostic, mobile phones, military applications require to handle large amount of data at high rate. Images as well as voice data processing are therefore very important and they have been subjected to a lot of efforts in order to find always faster and effective algorithms. Among image processing algorithms, we believe that rational operators assume an important role, due to their versatility and effectiveness in data processing. In the last years, several algorithms have been proposed, demonstrating that these operators can be very suitable in different applications with very good results. The aim of this work is to implement some of these algorithm and, therefore, demonstrate that rational filters, in particular, can be implemented without requiring large sized systems and they can operate at very high frequencies. Once the basic building block of a rational based system has been implemented, it can be successfully reused in many other applications. From the designer point of view, it is important to have a general framework, which makes it able to study various configurations of the system to be implemented and analyse the trade-off among the design variables. In particular, to meet the need far versatile tools far power estimation, we developed a new macro modelling technique, which allows the designer to estimate the power dissipated by a circuit quickly and accurately. The thesis is organized as follows: In chapter 1 we present some of the algorithms which have been studied for implementation. Only a brief overview is given, leaving to the interested reader some references in literature. In chapter 2 we discuss the basic architectures used for the implementations. Pipelined structures have been mainly used for this thesis, but an overview of the nowaday available approaches for timing optimization is presented. In chapter 3 we present two of the implementation designed for this thesis. The approaches followed are ASIC driven and FPGA drive. They require different techniques and different solution for the design of the system, therefore it is interesting to see what can be done in both the cases. Finally, in chapter 4, we describe our macro modelling techniques for power estimation, giving a brief overview of the up to now proposed techniques and showing the advantages our method brings to the design. XII Ciclo 1969 Versione digitalizzata della tesi di dottorato cartacea.
- Published
- 2000
22. THREE-DIMENSIONAL VISION FOR STRUCTURE AND MOTION ESTIMATION
- Author
-
FUSIELLO, ANDREA, TRUCCO, EMANUELE, and LONGO, O. GIUSEPPE
- Subjects
INGEGNERIA DELL'INFORMAZIONE - Abstract
1997/1998 Questa tesi, intitolata Visione Tridimensionale per la stima di Struttura e Moto, tratta di tecniche di Visione Artificiale per la stima delle proprietà geometriche del mondo tridimensionale a partire da immagini numeriche. Queste proprietà sono essenziali per il riconoscimento e la classificazione di oggetti, la navigazione di veicoli mobili autonomi, il reverse engineering e la sintesi di ambienti virtuali. In particolare, saranno descritti i moduli coinvolti nel calcolo della struttura della scena a partire dalle immagini, e verranno presentati contributi originali nei seguenti campi. Rettificazione di immagini steroscopiche. Viene presentato un nuovo algoritmo per la rettificazione, il quale trasforma una coppia di immagini stereoscopiche in maniera che punti corrispondenti giacciano su linee orizzontali con lo stesso indice. Prove sperimentali dimostrano il corretto comportamento del metodo, come pure la trascurabile perdita di accuratezza nella ricostruzione tridimensionale quando questa sia ottenuta direttamente dalle immagini rettificate. Calcolo delle corrispondenze in immagini stereoscopiche. Viene analizzato il problema della stereovisione e viene presentato un un nuovo ed efficiente algoritmo per l'identificazione di coppie di punti corrispondenti, capace di calcolare in modo robusto la disparità stereoscopica anche in presenza di occlusioni. L'algoritmo, chiamato SMW, usa uno schema multi-finestra adattativo assieme al controllo di coerenza destra-sinistra per calcolare la disparità e l'incertezza associata. Gli esperimenti condotti con immagini sintetiche e reali mostrano che SMW sortisce un miglioramento in accuratezza ed efficienza rispetto a metodi simili Inseguimento di punti salienti. L'inseguitore di punti salienti di Shi-Tomasi- Kanade viene migliorato introducendo uno schema automatico per lo scarto di punti spuri basato sulla diagnostica robusta dei campioni periferici ( outliers ). Gli esperimenti con immagini sintetiche e reali confermano il miglioramento rispetto al metodo originale, sia qualitativamente che quantitativamente. Ricostruzione non calibrata. Viene presentata una rassegna ragionata dei metodi per la ricostruzione di un modello tridimensionale della scena, a partire da una telecamera che si muove liberamente e di cui non sono noti i parametri interni. Il contributo consiste nel fornire una visione critica e unificata delle più recenti tecniche. Una tale rassegna non esiste ancora in letterarura. Moto tridimensionale. Viene proposto un algoritmo robusto per registrate e calcolare le corrispondenze in due insiemi di punti tridimensionali nei quali vi sia un numero significativo di elementi mancanti. Il metodo, chiamato RICP, sfrutta la stima robusta con la Minima Mediana dei Quadrati per eliminare l'effetto dei campioni periferici. Il confronto sperimentale con una tecnica simile, ICP, mostra la superiore robustezza e affidabilità di RICP. This thesis addresses computer vision techniques estimating geometrie properties of the 3-D world /rom digital images. Such properties are essential for object recognition and classification, mobile robots navigation, reverse engineering and synthesis of virtual environments. In particular, this thesis describes the modules involved in the computation of the structure of a scene given some images, and offers original contributions in the following fields. Stereo pairs rectification. A novel rectification algorithm is presented, which transform a stereo pair in such a way that corresponding points in the two images lie on horizontal lines with the same index. Experimental tests prove the correct behavior of the method, as well as the negligible decrease oLthe accuracy of 3-D reconstruction if performed from the rectified images directly. Stereo matching. The problem of computational stereopsis is analyzed, and a new, efficient stereo matching algorithm addressing robust disparity estimation in the presence of occlusions is presented. The algorithm, called SMW, is an adaptive, multi-window scheme using left-right consistency to compute disparity and its associated uncertainty. Experiments with both synthetic and real stereo pairs show how SMW improves on closely related techniques for both accuracy and efficiency. Features tracking. The Shi-Tomasi-Kanade feature tracker is improved by introducing an automatic scheme for rejecting spurious features, based on robust outlier diagnostics. Experiments with real and synthetic images confirm the improvement over the original tracker, both qualitatively and quantitatively. 111 Uncalibrated vision. A review on techniques for computing a three-dimensional model of a scene from a single moving camera, with unconstrained motion and unknown parameters is presented. The contribution is to give a critical, unified view of some of the most promising techniques. Such review does not yet exist in the literature. 3-D motion. A robust algorithm for registering and finding correspondences in two sets of 3-D points with significant percentages of missing data is proposed. The method, called RICP, exploits LMedS robust estimation to withstand the effect of outliers. Experimental comparison with a closely related technique, ICP, shows RICP's superior robustness and reliability. XI Ciclo 1968 Versione digitalizzata della tesi di dottorato cartacea.
- Published
- 1999
23. ADAPTIVE AND NONLINEAR SIGNAL PROCESSING
- Author
-
CARINI, ALBERTO, SICURANZA, GIOVANNI, and LONGO, O. GIUSEPPE
- Subjects
INGEGNERIA DELL'INFORMAZIONE - Abstract
1996/1997 X Ciclo 1967 Versione digitalizzata della tesi di dottorato cartacea.
- Published
- 1997
24. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
- Author
-
Ensoli B, Nchabeleng M, Ensoli F, Tripiciano A, Bellino S, Picconi O, Sgadari C, Longo O, Tavoschi L, Joffe D, Cafaro A, Francavilla V, Moretti S, Pavone Cossut MR, Collacchi B, Arancio A, Paniccia G, Casabianca A, Magnani M, Buttò S, Levendal E, Ndimande JV, Asia B, Pillay Y, Garaci E, and Monini P
- Subjects
- AIDS Vaccines administration & dosage, AIDS Vaccines adverse effects, Adolescent, Adult, Antiretroviral Therapy, Highly Active, Cross Reactions, Female, HIV Infections virology, Humans, Immunization Schedule, Immunogenicity, Vaccine, Male, Middle Aged, South Africa, Vaccination, Viral Load, Young Adult, AIDS Vaccines immunology, Antibodies, Neutralizing blood, CD4-Positive T-Lymphocytes immunology, HIV Antibodies blood, HIV Infections immunology, HIV Infections therapy, HIV-1 immunology, tat Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Background: Although combined antiretroviral therapy (cART) has saved millions of lives, it is incapable of full immune reconstitution and virus eradication. The transactivator of transcription (Tat) protein is a key human immunodeficiency virus (HIV) virulence factor required for virus replication and transmission. Tat is expressed and released extracellularly by infected cells also under cART and in this form induces immune dysregulation, and promotes virus reactivation, entry and spreading. Of note, anti-Tat antibodies are rare in natural infection and, when present, correlate with asymptomatic state and reduced disease progression. This suggested that induction of anti-Tat antibodies represents a pathogenesis-driven intervention to block progression and to intensify cART. Indeed Tat-based vaccination was safe, immunogenic and capable of immune restoration in an open-label, randomized phase II clinical trial conducted in 168 cART-treated volunteers in Italy. To assess whether B-clade Tat immunization would be effective also in patients with different genetic background and infecting virus, a phase II trial was conducted in South Africa., Methods: The ISS T-003 was a 48-week randomised, double-blinded, placebo-controlled trial to evaluate immunogenicity (primary endpoint) and safety (secondary endpoint) of B-clade Tat (30 μg) given intradermally, three times at 4-week intervals, in 200 HIV-infected adults on effective cART (randomised 1:1) with CD4(+) T-cell counts ≥200 cells/µL. Study outcomes also included cross-clade anti-Tat antibodies, neutralization, CD4(+) T-cell counts and therapy compliance., Results: Immunization was safe and well-tolerated and induced durable, high titers anti-Tat B-clade antibodies in 97 % vaccinees. Anti-Tat antibodies were cross-clade (all vaccinees tested) and neutralized Tat-mediated entry of oligomeric B-clade and C-clade envelope in dendritic cells (24 participants tested). Anti-Tat antibody titers correlated positively with neutralization. Tat vaccination increased CD4(+) T-cell numbers (all participants tested), particularly when baseline levels were still low after years of therapy, and this had a positive correlation with HIV neutralization. Finally, in cART non-compliant patients (24 participants), vaccination contained viral load rebound and maintained CD4(+) T-cell numbers over study entry levels as compared to placebo., Conclusions: The data indicate that Tat vaccination can restore the immune system and induces cross-clade neutralizing anti-Tat antibodies in patients with different genetic backgrounds and infecting viruses, supporting the conduct of phase III studies in South Africa. Trial registration ClinicalTrials.gov NCT01513135, 01/23/2012.
- Published
- 2016
- Full Text
- View/download PDF
25. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.
- Author
-
Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, and Ensoli B
- Subjects
- AIDS Vaccines adverse effects, Acquired Immunodeficiency Syndrome immunology, Adult, Antibodies, Neutralizing blood, CD4 Lymphocyte Count, Female, Follow-Up Studies, Humans, Immunoglobulin G blood, Immunoglobulin M blood, Italy, Leukocytes immunology, Male, Middle Aged, Treatment Outcome, Young Adult, AIDS Vaccines administration & dosage, AIDS Vaccines immunology, Acquired Immunodeficiency Syndrome therapy, Antiretroviral Therapy, Highly Active methods, HIV Antibodies blood, Viral Load, tat Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Background: The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov NCT00751595) was aimed at evaluating the immunogenicity and the safety of the biologically active HIV-1 Tat protein administered at 7.5 or 30 μg, given 3 or 5 times monthly, and at exploring immunological and virological disease biomarkers. The study duration was 48 weeks, however, vaccinees were followed until the last enrolled subject reached the 48 weeks. Reported are final data up to 144 weeks of follow-up. The ISS T-002 trial was conducted in 11 clinical centers in Italy on 168 HIV positive subjects under Highly Active Antiretroviral Therapy (HAART), anti-Tat Antibody (Ab) negative at baseline, with plasma viremia <50 copies/mL in the last 6 months prior to enrollment, and CD4(+) T-cell number ≥200 cells/μL. Subjects from a parallel observational study (ISS OBS T-002, Clinicaltrials.gov NCT0102455) enrolled at the same clinical sites with the same criteria constituted an external reference group to explore biomarkers of disease., Results: The vaccine was safe and well tolerated and induced anti-Tat Abs in most patients (79%), with the highest frequency and durability in the Tat 30 μg groups (89%) particularly when given 3 times (92%). Vaccination promoted a durable and significant restoration of T, B, natural killer (NK) cells, and CD4(+) and CD8(+) central memory subsets. Moreover, a significant reduction of blood proviral DNA was seen after week 72, particularly under PI-based regimens and with Tat 30 μg given 3 times (30 μg, 3x), reaching a predicted 70% decay after 3 years from vaccination with a half-life of 88 weeks. This decay was significantly associated with anti-Tat IgM and IgG Abs and neutralization of Tat-mediated entry of oligomeric Env in dendritic cells, which predicted HIV-1 DNA decay. Finally, the 30 μg, 3x group was the only one showing significant increases of NK cells and CD38(+)HLA-DR(+)/CD8(+) T cells, a phenotype associated with increased killing activity in elite controllers., Conclusions: Anti-Tat immune responses are needed to restore immune homeostasis and effective anti-viral responses capable of attacking the virus reservoir. Thus, Tat immunization represents a promising pathogenesis-driven intervention to intensify HAART efficacy.
- Published
- 2015
- Full Text
- View/download PDF
26. Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner.
- Author
-
Chiozzini C, Collacchi B, Nappi F, Bauer T, Arenaccio C, Tripiciano A, Longo O, Ensoli F, Cafaro A, Ensoli B, and Federico M
- Subjects
- Adult, Apoptosis, CD8-Positive T-Lymphocytes pathology, Female, Humans, Male, Young Adult, CD8-Positive T-Lymphocytes immunology, HIV-1 physiology, Host-Pathogen Interactions, Integrins metabolism, tat Gene Products, Human Immunodeficiency Virus metabolism
- Abstract
Objective: The identification of still unrevealed mechanisms affecting the anti-HIV CD8 T-cell response in HIV-1 infection., Design: Starting from the observation that anti-Tat immunization is associated with improved CD8 T-cell immunity, we developed both in-vitro and ex-vivo assays to characterize the effects of extra-cellular Tat on the adaptive CD8 T-cell response., Methods: The effects of Tat on CD8 T-cell activation were assayed using CD8 T-cell clones specific for either cellular (MART-1) or viral (HIV-1 Nef) antigens, and HIV-1 Gag-specific CD8 T cells from HIV-1 patients., Results: The interaction between CD8 T lymphocytes and immobilized Tat, but not its soluble form, inhibits peptide-specific CD8 T-lymphocyte activation. The inhibition does not depend on Tat trans-activation activity, but on the interaction of the Tat RGD domain with α5β1 and αvβ3 integrins. Impaired CD8 T-cell activation was also observed in cocultures of CD8 T cells with HIV-1-infected cells. Anti-Tat Abs abrogate the inhibitory effect, consistently with the evidence that extracellular Tat accumulates on the cell membrane of virus-producing cells. The Tat-induced inhibition of cell activation associates with increased apoptosis of CD8 T cells. Finally, the inhibition of cell activation also takes place in Gag-specific CD8 T lymphocytes from HIV-1-infected patients., Conclusion: Our results support the idea that CD8 T-cell apoptosis induced by surface-bound extracellular Tat can contribute to the dysregulation of the CD8 T-cell adaptive response against HIV as well as other pathogens present in AIDS patients.
- Published
- 2014
- Full Text
- View/download PDF
27. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.
- Author
-
Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, and Ensoli B
- Subjects
- AIDS Vaccines administration & dosage, AIDS Vaccines immunology, Adult, Cohort Studies, Disease Progression, Female, Gene Products, env immunology, Genes, env immunology, HIV Infections virology, Humans, Male, Viral Load, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, CD4-Positive T-Lymphocytes immunology, HIV Infections immunology, HIV-1 immunology, tat Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Background: Tat is a key HIV-1 virulence factor, which plays pivotal roles in virus gene expression, replication, transmission and disease progression. After release, extracellular Tat accumulates in tissues and exerts effects on both the virus and the immune system, promoting immune activation and virus spreading while disabling the host immune defense. In particular, Tat binds Env spikes on virus particles forming a virus entry complex, which favors infection of dendritic cells and efficient transmission to T cells via RGD-binding integrins. Tat also shields the CCR5-binding sites of Env rendering ineffective virus neutralization by anti-Env antibodies (Abs). This is reversed by the anti-Tat Abs present in natural infection or induced by vaccination., Findings: Here we present the results of a cohort study, showing that the presence of anti-Tat Abs in asymptomatic and treatment-naïve HIV-infected subjects is associated with containment of CD4+ T-cell loss and viral load and with a delay of disease progression. In fact, no subjects with high anti-Tat Ab titers initiated antiretroviral therapy during the three years of follow-up. In contrast, no significant effects were seen for anti-Env and anti-Gag Abs. The increase of anti-Env Ab titers was associated with a reduced risk of starting therapy only in the presence of anti-Tat Abs, suggesting an effect of combined anti-Tat and anti-Env Abs on the Tat/Env virus entry complex and on virus neutralization., Conclusions: Anti-Tat immunity may help delay HIV disease progression, thus, targeting Tat may offer a novel therapeutic intervention to postpone antiretroviral treatment or to increase its efficacy.
- Published
- 2014
- Full Text
- View/download PDF
28. HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.
- Author
-
Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A, Nappi F, Longo O, Bellino S, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone P, Leone P, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MP, Titti F, Banci L, Dallocchio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, and Ensoli B
- Subjects
- AIDS Vaccines administration & dosage, AIDS Vaccines immunology, Animals, Antibodies, Neutralizing immunology, Antibodies, Neutralizing metabolism, Binding Sites, Dendritic Cells immunology, HIV Antibodies immunology, HIV Envelope Protein gp120 immunology, HIV Envelope Protein gp120 metabolism, HIV Infections immunology, HIV Infections prevention & control, HIV Infections transmission, HIV Infections virology, HIV-1 immunology, Humans, Integrins immunology, Macaca fascicularis, Male, Molecular Docking Simulation, Neutralization Tests, Oligopeptides metabolism, Protein Binding, Protein Interaction Domains and Motifs immunology, Receptors, CCR5 metabolism, Receptors, CXCR4 metabolism, Recombinant Proteins immunology, Recombinant Proteins isolation & purification, Recombinant Proteins metabolism, T-Lymphocytes immunology, T-Lymphocytes metabolism, T-Lymphocytes virology, Vaccines, Virus-Like Particle administration & dosage, Vaccines, Virus-Like Particle immunology, Virus Internalization, Virus Replication, env Gene Products, Human Immunodeficiency Virus chemistry, env Gene Products, Human Immunodeficiency Virus immunology, tat Gene Products, Human Immunodeficiency Virus chemistry, tat Gene Products, Human Immunodeficiency Virus immunology, Dendritic Cells virology, HIV Antibodies metabolism, HIV-1 metabolism, Integrins metabolism, env Gene Products, Human Immunodeficiency Virus metabolism, tat Gene Products, Human Immunodeficiency Virus metabolism
- Abstract
Use of Env in HIV vaccine development has been disappointing. Here we show that, in the presence of a biologically active Tat subunit vaccine, a trimeric Env protein prevents in monkeys virus spread from the portal of entry to regional lymph nodes. This appears to be due to specific interactions between Tat and Env spikes that form a novel virus entry complex favoring R5 or X4 virus entry and productive infection of dendritic cells (DCs) via an integrin-mediated pathway. These Tat effects do not require Tat-transactivation activity and are blocked by anti-integrin antibodies (Abs). Productive DC infection promoted by Tat is associated with a highly efficient virus transmission to T cells. In the Tat/Env complex the cysteine-rich region of Tat engages the Env V3 loop, whereas the Tat RGD sequence remains free and directs the virus to integrins present on DCs. V2 loop deletion, which unshields the CCR5 binding region of Env, increases Tat/Env complex stability. Of note, binding of Tat to Env abolishes neutralization of Env entry or infection of DCs by anti-HIV sera lacking anti-Tat Abs, which are seldom present in natural infection. This is reversed, and neutralization further enhanced, by HIV sera containing anti-Tat Abs such as those from asymptomatic or Tat-vaccinated patients, or by sera from the Tat/Env vaccinated monkeys. Thus, both anti-Tat and anti-Env Abs are required for efficient HIV neutralization. These data suggest that the Tat/Env interaction increases HIV acquisition and spreading, as a mechanism evolved by the virus to escape anti-Env neutralizing Abs. This may explain the low effectiveness of Env-based vaccines, which are also unlikely to elicit Abs against new Env epitopes exposed by the Tat/Env interaction. As Tat also binds Envs from different clades, new vaccine strategies should exploit the Tat/Env interaction for both preventative and therapeutic interventions.
- Published
- 2012
- Full Text
- View/download PDF
29. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.
- Author
-
Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez MJ, Campagna M, Scaramuzzi D, Iori C, Esposito R, Mussini C, Ghinelli F, Sighinolfi L, Palamara G, Latini A, Angarano G, Ladisa N, Soscia F, Mercurio VS, Lazzarin A, Tambussi G, Visintini R, Mazzotta F, Di Pietro M, Galli M, Rusconi S, Carosi G, Torti C, Di Perri G, Bonora S, Ensoli F, and Garaci E
- Subjects
- AIDS Vaccines immunology, Adult, Aged, Asthenia etiology, B-Lymphocytes immunology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Combined Modality Therapy, Female, HIV Infections therapy, HIV Infections virology, HIV-1 metabolism, Homeostasis immunology, Humans, Immunization adverse effects, Immunization methods, Killer Cells, Natural immunology, Lymphocyte Activation, Male, Middle Aged, Nausea etiology, Prospective Studies, T-Lymphocytes, Regulatory metabolism, Treatment Outcome, Antiretroviral Therapy, Highly Active, HIV Infections immunology, HIV-1 immunology, T-Lymphocytes, Regulatory immunology, tat Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Unlabelled: Although HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated individuals. This is attributed to persistent virus expression in reservoirs and to cell activation. Of note, in CD4(+) T cells and monocyte-macrophages of virologically-suppressed individuals, there is continued expression of multi-spliced transcripts encoding HIV regulatory proteins. Among them, Tat is essential for virus gene expression and replication, either in primary infection or for virus reactivation during HAART, when Tat is expressed, released extracellularly and exerts, on both the virus and the immune system, effects that contribute to disease maintenance. Here we report results of an ad hoc exploratory interim analysis (up to 48 weeks) on 87 virologically-suppressed HAART-treated individuals enrolled in a phase II randomized open-label multicentric clinical trial of therapeutic immunization with Tat (ISS T-002). Eighty-eight virologically-suppressed HAART-treated individuals, enrolled in a parallel prospective observational study at the same sites (ISS OBS T-002), served for intergroup comparison. Immunization with Tat was safe, induced durable immune responses, and modified the pattern of CD4(+) and CD8(+) cellular activation (CD38 and HLA-DR) together with reduction of biochemical activation markers and persistent increases of regulatory T cells. This was accompanied by a progressive increment of CD4(+) T cells and B cells with reduction of CD8(+) T cells and NK cells, which were independent from the type of antiretroviral regimen. Increase in central and effector memory and reduction in terminally-differentiated effector memory CD4(+) and CD8(+) T cells were accompanied by increases of CD4(+) and CD8(+) T cell responses against Env and recall antigens. Of note, more immune-compromised individuals experienced greater therapeutic effects. In contrast, these changes were opposite, absent or partial in the OBS population. These findings support the use of Tat immunization to intensify HAART efficacy and to restore immune homeostasis., Trial Registration: ClinicalTrials.gov NCT00751595.
- Published
- 2010
- Full Text
- View/download PDF
30. C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A.
- Author
-
Lamberti A, Longo O, Marra M, Tagliaferri P, Bismuto E, Fiengo A, Viscomi C, Budillon A, Rapp UR, Wang E, Venuta S, Abbruzzese A, Arcari P, and Caraglia M
- Subjects
- Cell Line, Tumor, Humans, Immunoprecipitation, Lung Neoplasms metabolism, Phosphorylation drug effects, Phosphoserine metabolism, Phosphothreonine metabolism, Proteasome Endopeptidase Complex metabolism, Protein Binding drug effects, Protein Processing, Post-Translational drug effects, Protein Transport drug effects, RNA, Small Interfering metabolism, Ubiquitin metabolism, Apoptosis drug effects, Interferon-alpha pharmacology, Lung Neoplasms pathology, Oncogene Proteins metabolism, Peptide Elongation Factor 1 metabolism, Proto-Oncogene Proteins c-raf metabolism
- Abstract
Interferon alpha (IFNalpha) induces both apoptosis and a counteracting epidermal growth factor Erk-dependent survival response in cancer cells. In this report, IFNalpha increased eukaryotic elongation factor 1A (eEF-1A) protein expression by inhibition of eEF-1A degradation via a proteasome-dependent pathway. The reduction of the expression level of eEF-1A by RNA interference enhanced the apoptosis induced by IFNalpha on the same cells. Moreover, IFNalpha induced the phosphorylation of both serine and threonine in eEF-1A. These effects were paralleled by an increased co-immunoprecipitation and colocalization of eEF-1A with C-Raf. The suppression of C-Raf kinase activity with the inhibitor BAY 43-9006 completely antagonized the increase of both eEF-1A phosphorylation and expression and of C-Raf/eEF-1A colocalization induced by IFNalpha and enhanced apoptosis and eEF-1A ubiquitination. Cell transfection with the mutated K48R ubiquitin increased EF-1A expression and desensitized tumor cells to the modulating effects of IFNalpha. The dynamic simulation of 3Dstructure of eEF-1A identified putative serine and threonine phosphorylation sites. In conclusion, the interaction between eEF-1A and C-Raf increases eEF-1A stability and induces a survival activity.
- Published
- 2007
- Full Text
- View/download PDF
31. Probing the secondary structure of a recombinant neuronal adaptor protein and its phosphotyrosine binding domains.
- Author
-
Lamberti A, Longo O, Del Vecchio P, Zambrano N, Barone G, Russo T, and Arcari P
- Subjects
- Animals, Binding Sites, Blotting, Western, Brain Chemistry physiology, Circular Dichroism, Gene Expression, Hydrolysis, Nerve Tissue Proteins genetics, Nerve Tissue Proteins metabolism, Nuclear Proteins genetics, Nuclear Proteins metabolism, Plasmids genetics, Protein Binding, Protein Structure, Secondary, Rats, Recombinant Proteins chemistry, Recombinant Proteins metabolism, Spectrometry, Fluorescence, Spectrophotometry, Ultraviolet, Nerve Tissue Proteins chemistry, Nuclear Proteins chemistry, Phosphotyrosine metabolism
- Abstract
Rat brain Fe65 and its truncated forms corresponding to the combined PTB1 and PTB2 domains, as well as to the isolated PTB2 domain, were expressed in Escherichia coli and purified from inclusion bodies by affinity chromatography. The recombinant proteins were refolded and judged functionally active by their ability to interact with native APP. Limited proteolysis of recombinant Fe65 and PTB1-2 with trypsin, chymotrypsin and V8 proteases showed that the most sensitive proteoltytic sites were positioned at the level of the interdomain regions comprised between WW/PTB1 and PTB1/PTB2. Secondary structure of the recombinant proteins, evaluated by CD spectroscopy, showed a different degree of unordered structures, the PTB2 domain being the higher organised region. In addition, intrinsic fluorescence measurements of PTB2, indicated that a conformational transition of the protein can be induced by denaturating agents such as GuHCl. These data provide first evidences on the secondary structural levels of Fe65.
- Published
- 2005
- Full Text
- View/download PDF
32. A long acidic domain affects the chromatographic behaviour of a neuronal adaptor protein on DEAE-Sepharose.
- Author
-
Longo O, Lamberti A, Zambrano N, and Arcari P
- Subjects
- Animals, Blotting, Western, Calcium Chloride chemistry, Calcium Chloride metabolism, Chromatography, Liquid instrumentation, Chromatography, Liquid methods, Magnesium Chloride chemistry, Magnesium Chloride metabolism, Nerve Tissue Proteins metabolism, Nuclear Proteins metabolism, Osmolar Concentration, Peptide Fragments chemistry, Peptide Fragments metabolism, Protein Structure, Tertiary, Rats, Nerve Tissue Proteins chemistry, Nuclear Proteins chemistry, Sepharose analogs & derivatives, Sepharose metabolism
- Abstract
The stepwise chromatographic behaviour on DEAE-Sepharose of rat Fe65, a neuronal protein, was tested, using as eluants KCl, CaCl2, and MgCl2. Assays by western blot showed that Fe65 was eluted by CaCl2, at a ionic strength 20% lower than that of MgCl2 or KCl. Interestingly, in the case of a truncated Fe65, lacking a glutamic acid rich region at the N-terminus, the ionic strengths of the various eluants were almost identical. These results suggested a possible inhibitory role of calcium ions in the binding of the protein to DEAE and a specific affinity of these ions for long acidic stretches.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.